Geode Capital Management
ADVM

Geode Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Geode Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-184,762
Closed -$837K – 4472
2025
Q3 		$837K Hold
184,762
– – ﹤0.01% 3442
2025
Q2 		$397K Sell
184,762
-266,496
-59% -$745K ﹤0.01% 3630
2025
Q1 		$1.97M Buy
451,258
+8,768
+2% +$39.5K ﹤0.01% 3034
2024
Q4 		$2.07M Buy
442,490
+3,434
+0.8% +$23.1K ﹤0.01% 3107
2024
Q3 		$3.08M Sell
439,056
-16,731
-4% -$121K ﹤0.01% 2976
2024
Q2 		$3.13M Buy
455,787
+262,271
+136% +$2.44M ﹤0.01% 2963
2024
Q1 		$2.74M Buy
193,516
+107,095
+124% +$1.63M ﹤0.01% 2988
2023
Q4 		$651K Hold
86,421
– – ﹤0.01% 3519
2023
Q3 		$1.3M Sell
86,421
-2,284
-3% -$41K ﹤0.01% 3223
2023
Q2 		$1.41M Buy
88,705
+9,915
+13% +$104K ﹤0.01% 3222
2023
Q1 		$565K Buy
78,790
+1,575
+2% +$11.1K ﹤0.01% 3595
2022
Q4 		$447K Buy
77,215
+1,656
+2% +$12.6K ﹤0.01% 3709
2022
Q3 		$717K Buy
75,559
+259
+0.3% +$3.4K ﹤0.01% 3552
2022
Q2 		$903K Sell
75,300
-67,264
-47% -$705K ﹤0.01% 3474
2022
Q1 		$1.87M Sell
142,564
-15,189
-10% -$222K ﹤0.01% 3289
2021
Q4 		$2.78M Buy
157,753
+4,360
+3% +$87.3K ﹤0.01% 3205
2021
Q3 		$3.33M Sell
153,393
-6,676
-4% -$170K ﹤0.01% 3142
2021
Q2 		$5.6M Buy
160,069
+9,702
+6% +$523K ﹤0.01% 2822
2021
Q1 		$14.8M Buy
150,367
+13,926
+10% +$1.67M ﹤0.01% 2073
2020
Q4 		$14.8M Buy
136,441
+6,747
+5% +$835K ﹤0.01% 1900
2020
Q3 		$13.4M Buy
129,694
+24,986
+24% +$3.74M ﹤0.01% 1784
2020
Q2 		$21.9M Buy
104,708
+13,761
+15% +$2.44M ﹤0.01% 1454
2020
Q1 		$8.88M Buy
90,947
+13,968
+18% +$1.63M ﹤0.01% 1804
2019
Q4 		$8.87M Sell
76,979
-4,315
-5% -$380K ﹤0.01% 2093
2019
Q3 		$4.43M Buy
81,294
+346
+0.4% +$39K ﹤0.01% 2453
2019
Q2 		$9.62M Buy
80,948
+1,686
+2% +$140K ﹤0.01% 1983
2019
Q1 		$4.15M Buy
79,262
+9,402
+13% +$380K ﹤0.01% 2437
2018
Q4 		$2.2M Buy
69,860
+11,517
+20% +$468K ﹤0.01% 2724
2018
Q3 		$3.53M Buy
58,343
+12,383
+27% +$695K ﹤0.01% 2582
2018
Q2 		$2.44M Buy
45,960
+17,825
+63% +$1.07M ﹤0.01% 2742
2018
Q1 		$1.63M Buy
28,135
+18,610
+195% +$1.16M ﹤0.01% 2874
2017
Q4 		$333K Hold
9,525
– – ﹤0.01% 3503
2017
Q3 		$347K Hold
9,525
– – ﹤0.01% 3481
2017
Q2 		$238K Sell
9,525
-4,001
-30% -$109K ﹤0.01% 3615
2017
Q1 		$365K Buy
13,526
+408
+3% +$11.6K ﹤0.01% 3433
2016
Q4 		$380K Buy
13,118
+662
+5% +$21.6K ﹤0.01% 3371
2016
Q3 		$511K Buy
12,456
+219
+2% +$8.31K ﹤0.01% 3242
2016
Q2 		$386K Buy
12,237
+2,719
+29% +$123K ﹤0.01% 3328
2016
Q1 		$492 Buy
9,518
+145
+2% +$8.1K ﹤0.01% 3246
2015
Q4 		$892K Buy
9,373
+2,022
+28% +$178K ﹤0.01% 2969
2015
Q3 		$604K Buy
7,351
+490
+7% +$62.6K ﹤0.01% 3130
2015
Q2 		$1.11M Buy
6,861
+1,264
+23% +$426K ﹤0.01% 2835
2015
Q1 		$2.27M Buy
5,597
+1,122
+25% +$474K ﹤0.01% 2359
2014
Q4 		$2.42M Buy
4,475
+1,078
+32% +$416K ﹤0.01% 2310
2014
Q3 		$1.16M Buy
+3,397
New +$1.01M ﹤0.01% 2695

Geode Capital Management's ADVM Position: Q4 2025 in Review

Geode Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 184,762 shares — an estimated $837K sold.

Geode Capital Management first reported a position in ADVM in Q3 2014 and held it in 45 quarters. The position peaked at $21.9M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • Geode Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Geode Capital Management sold 184,762 Adverum Biotechnologies shares in Q4 2025, an estimated $837K.
  • Geode Capital Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 45 quarters.
  • Geode Capital Management's Adverum Biotechnologies position peaked at $21.9M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.